Enteric (typhoid and paratyphoid) fever
- PMID: 40914181
- DOI: 10.1016/S0140-6736(25)01335-2
Enteric (typhoid and paratyphoid) fever
Abstract
Enteric fever, caused by the human-restricted bacteria Salmonella enterica serovar Typhi (typhoid) and Salmonella enterica serovar Paratyphi A, B, and C (paratyphoid), affects persons residing in, or travelling from, areas lacking safe water, sanitation, and hygiene infrastructure. Transmission is by the faecal-oral route. A gradual fever onset over 3-7 days with malaise, headache, and myalgia is typical. Symptoms can be altered by previous antimicrobial use. Life-threatening complications can arise in the second week of untreated illness. Differentiation from other febrile illnesses is challenging. Blood or bone marrow culture remain reference standard diagnostic methods, despite the low sensitivity of blood culture. Azithromycin, ciprofloxacin (excepting cases originating in south Asia due to drug resistance), or ceftriaxone are recommended treatment options for both typhoid and paratyphoid; however, choice should be guided by local resistance patterns. Ciprofloxacin-resistant and ceftriaxone-resistant typhoid is common in Pakistan. Three vaccine types are available for prevention of typhoid disease, including the newer, more effective typhoid Vi-conjugate vaccines. Vaccination as well as water, sanitation, and hygiene measures are cornerstones of prevention.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests AK, FNQ, and CMP are involved in the ACT-South Asia trial, which is funded by a Joint Global Health Trials Scheme (MR/TOO5033/1) award to the University of Oxford. RK is involved in the Research, Evidence and Development Initiative (READ-It; project number 300342-104), which is funded by the UK government. All other authors declare no competing interests.
Publication types
LinkOut - more resources
Full Text Sources